Otamixaban - CAS 193153-04-7
Catalog number: 193153-04-7
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
Molecular Weight:
Factor Xa
Otamixaban, is a novel, selective, rapid acting, competitive, reversible and direct fXa inhibitor of the β-aminoester class. It was in Phase-III clinical development for cute coronary syndromes in 2013 but the clinical trial has discontinued now.
Publictions citing BOC Sciences Products
  • >> More
Solid powder
methyl (2R,3R)-2-[(3-carbamimidoylphenyl)methyl]-3-[[4-(1-oxidopyridin-1-ium-4-yl)benzoyl]amino]butanoate 2-(3-carbamimidoylbenzyl)-3-(4-(1-oxypyridin-4-yl)benzoylamino)butyric acid methyl ester 2-(R)-(3-carbamimidoylbenzyl)-3-(R)-(4-(1-oxypyridin-4-yl)be
Soluble in DMSO
Store in a cool and dry place and at 0 - 4℃ for short term (days to weeks) or -74℃ for long term (months to years).
A potent (Ki = 0.5 nM), selective, rapid acting, competitive and reversible fXa inhibitor that effectively inhibits both free and prothrombinase-bound fXa. Clinical studies show that it is efficacious, safe and well tolerated in humans and therefore has c
Shelf Life:
2 years
Data not available, please inquire.
1.25 g/cm3
Canonical SMILES:
1.Design and rationale of the treatment of acute coronary syndromes with otamixaban trial: a double-blind triple-dummy 2-stage randomized trial comparing otamixaban to unfractionated heparin and eptifibatide in non-ST-segment elevation acute coronary syndromes with a planned early invasive strategy.
Steg PG1, Mehta SR, Pollack CV Jr, Bode C, Gaudin C, Fanouillere K, Moryusef A, Wiviott SD, Sabatine MS. Am Heart J. 2012 Dec;164(6):817-24.e13. doi: 10.1016/j.ahj.2012.10.001. Epub 2012 Nov 7.
BACKGROUND: Otamixaban is a synthetic intravenous direct factor Xa inhibitor, with rapid onset/offset, linear kinetics, and no significant renal elimination. A phase II trial in acute coronary syndromes (ACS) showed a marked reduction in the combined end point of death or myocardial infarction (MI) and similar bleeding rates with otamixaban at midrange doses, compared with unfractionated heparin (UFH) and eptifibatide.
2.Anticoagulation with otamixaban and ischemic events in non-ST-segment elevation acute coronary syndromes: the TAO randomized clinical trial.
Steg PG1, Mehta SR, Pollack CV Jr, Bode C, Cohen M, French WJ, Hoekstra J, Rao SV, Ruzyllo W, Ruiz-Nodar JM, Sabaté M, Widimsky P, Kiss RG, Navarro Estrada JL, Hod H, Kerkar P, Guneri S, Sezer M, Ruda M, Nicolau JC, Cavallini C, Ebrahim I, Petrov I, Kim JH, Jeong MH, Ramos Lopez GA, Laanmets P, Kovar F, Gaudin C, Fanouillere KC, Minini P, Hoffman EB, Moryusef A, Wiviott SD, Sabatine MS; TAO Investigators. JAMA. 2013 Sep 18;310(11):1145-55. doi: 10.1001/jama.2013.277165.
IMPORTANCE: The optimal anticoagulant for patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACS) managed with an invasive strategy remains controversial.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Factor Xa Products

CAS 480449-70-5 Edoxaban

(CAS: 480449-70-5)

Edoxaban is an oral factor Xa (FXa) inhibitor, also contraindicated in patients with active pathological bleeding.

CAS 56974-61-9 Gabexate mesylate

Gabexate mesylate
(CAS: 56974-61-9)

Gabexate is a serine protease inhibitor that inhibits trypsin (IC50= 9.4μM), plasmin (IC50= 30μM), plasma kallikrein (IC50= 41μM) and thrombin (IC50= 110μM). It...

CAS 503612-47-3 Apixaban

(CAS: 503612-47-3)

Apixaban (INN, trade name Eliquis) is an anticoagulant for the prevention of venous thromboembolism and the prevention of stroke in atrial fibrillation. It is a...

CAS 536748-46-6 Eribaxaban

(CAS: 536748-46-6)

Eribaxaban is an orally active inhibitor of coagulation factor Xa (activated factor X). It has anticoagulant activity and is used as an anticoagulant drug. It i...

CAS 280118-23-2 BMS-740808

(CAS: 280118-23-2)

BMS-740808 is a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa with Ki of 0.03 nM.

CAS 1229194-11-9 Edoxaban tosylate monohydrate

Edoxaban tosylate monohydrate
(CAS: 1229194-11-9)

In human plasma, Edoxaban doubles prothrombin time and activates partial thromboplastin time at 0.256 and 0.508 μM, respectively

CAS 288079-93-6 BMS-344577

(CAS: 288079-93-6)

BMS-344577 is aroylguanidine-based lactam derivative, which is a potent FXa inhibitor (FXa IC(50)=4 nM, EC(2xPT)=7 microM).

CAS 130952-46-4 Ozagrel sodium

Ozagrel sodium
(CAS: 130952-46-4)

The sodium salt form of Ozagrel which has been studied to influence monophenolase and diphenolase activities and also restrain the synthesis of thromboxane A2 s...

CAS 480449-71-6 Edoxaban TsOH salt

Edoxaban TsOH salt
(CAS: 480449-71-6)

Edoxaban is an oral factor Xa (FXa) inhibitor, also contraindicated in patients with active pathological bleeding.

CAS 366789-02-8 Rivaroxaban

(CAS: 366789-02-8)

Rivaroxaban (Xarelto; BAY 59-7939) is a novel, oral, direct Factor Xa (FXa) inhibitor in late-stage development for the prevention and treatment of thromboembol...

CAS 193153-04-7 Otamixaban

(CAS: 193153-04-7)

Otamixaban, is a novel, selective, rapid acting, competitive, reversible and direct fXa inhibitor of the β-aminoester class. It was in Phase-III clinical develo...

CAS 330942-05-7 betrixaban

(CAS: 330942-05-7)

Betrixaban is a long-acting anticoagulant used for the treatment of venous thromboembolism (VTE) caused by limited mobility or some other factors in adult patie...

Chemical Structure

CAS 193153-04-7 Otamixaban

Quick Inquiry

Verification code

Featured Items